Immunogenicity and Safety Study of 1 and 2 Doses of Meningococcal Vaccine MenACWY-TT in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13® Vaccine
A Phase III, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity and Persistence of 1 and 2 Doses of Meningococcal Conjugate Vaccine MenACWY-TT in Toddlers (After 1 Month and up to 5 Years) and to Demonstrate Non-Inferiority of Co-Administration of MenACWY-TT and 13-Valent Pneumococcal Conjugate Vaccine Prevenar 13® Versus Separate Administration of the 2 Vaccines
Category & Conditions: Vaccine-related Conditions
Medicine: Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine)
PREVNAR 13(PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN])
ClinicalTrials.gov Identifier (NCT): NCT01939158
Protocol ID: C0921003
PrintDownloadOpen Plain Language Summary Result: Click here